The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences has its own resident expert in the fields of ...

Antibody-drug conjugates have emerged as ... “Advancements in ADCs could potentially spur biosimilar competition; however, the complex design of ADCs presents a greater challenge for rivals.

A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical curcumin gel) in osteoarthritis (OA) is underway. The study is being conducted at Clinical Research ...

The global Central Lab Services/Clinical Trial Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

Researchers studying Alzheimer’s disease are using artificial intelligence-powered databases to accelerate the drug discovery process by making it easier to sift through vast amounts of biomedical ...

Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...